Verekitug in Severe asthma: NCT06966479 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Active, not recruiting
Recruitment status
396
Planned enrollment
2027-09-01
Primary-completion proxy
Executive view
NCT06966479 evaluates Verekitug in Severe asthma. The disclosed sponsor is Upstream Bio, Inc., the design is Interventional, and the geographic footprint is Argentina, Czechia, United States, Japan, Ukraine, United Kingdom, Spain, Canada, South Korea, Poland, South Africa, Italy, Chile, Bulgaria, Germany. The first listed primary endpoint is Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), assessed over From VALOUR baseline up to Week 64.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06966479 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Severe asthma landscape. Drug & Asset MCP drug_fetch was queried for Verekitug, while Company & Deal Intelligence MCP organization_fetch was queried for Upstream Bio, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT06966479 | Verekitug | Phase 2 / Active, not recruiting | Upstream Bio, Inc. | Argentina, Czechia, United States, Japan, Ukraine, United Kingdom, Spain, Canada, South Korea, Poland, South Africa, Italy, Chile, Bulgaria, Germany | Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) From VALOUR baseline up to Week 64 | 2027-09-01 |
| NCT07363642 | Tezepelumab | Phase 3 / Recruiting | AstraZeneca PLC | China | To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in… within 36 weeks after the first administration | 2028-02-07 |
| NCT07359846 | GB-0895 | Phase 3 / Recruiting | Generate Biomedicines, Inc. | Argentina, United States, Japan, Ukraine, United Kingdom, Spain, Belgium, Turkey, Italy, Slovakia, Serbia, France, Australia, Estonia | To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled as… From Day 1 (randomization) to Week 52 | 2029-01-01 |
| NCT07343661 | Mepolizumab | Phase 4 / Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | Italy | Saliva, sputum, and plasma proteomic profile of EGPA patients From the data to the enrollment until the end of the study, up to 52… | 2026-10-17 |
| NCT07276724 | GB-0895 | Phase 3 / Recruiting | Generate Biomedicines, Inc. | Greece, Netherlands, Latvia, Romania, Hungary, Czechia, United States, South Africa, Bulgaria, Portugal, Germany | To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled as… From Day 1 (randomization) to Week 52 | 2028-12-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT06966479 is a Phase 2, active, not recruiting study with 396 planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment.
The primary endpoint is “Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)” over “From VALOUR baseline up to Week 64.” The retrieved endpoint description is: An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 396 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Severe asthma. These records do not establish direct evidence for NCT06966479 unless the registration number matches.
Tezepelumab in the Framework of Use in Special Situations Before Commercialization: T-ROSS, a Retrospective Real-world Study in Spain
Not Applicable; n=33; clinical remission = 13.8 % Source: https://pubmed.ncbi.nlm.nih.gov/42002456/
B32-32 Evolution in the Use of Biologics Among US Adults With Severe Asthma: Data From the CHRONICLE Study
Not Applicable; n=4366; Biologic initiation(From December 2021 to February 2025) = 31.1 % ; Biologic initiation(From December 2021 to February 2025) = 33.2 % Source: https://academic.oup.com/ajrccm/article/212/Supplement_1/aamag162.472/8679419
A36-12 The Asthma Treatment Paradox: High Steroids, Low Controllers, and Fewer Biologics
Not Applicable; n=740; Biologic therapy utilization = 11.3 % Source: https://academic.oup.com/ajrccm/article/212/Supplement_1/aamag162.339/8679805
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Verekitug is indexed as Monoclonal antibody with TSLPR biology and a global stage of Phase 2. The asset profile lists Upstream Bio, Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Upstream Bio, Inc.. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Verekitug is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT06966479
Protocol source: https://clinicaltrials.gov/study/NCT06966479
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
Verekitug in Severe asthma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) and 2027-09-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
